Aditxt, Inc. (NASDAQ: ADTX), an innovation platform aimed at accelerating health advancements, has announced that its majority-owned subsidiary, Pearsanta, Inc., has entered into a Market Development Collaboration Agreement with Evofem Biosciences, a leader in women’s health. This partnership will focus on Pearsanta’s blood-based diagnostic test for endometriosis.
Endometriosis is a chronic condition that causes severe pain and affects about one in ten women of reproductive age globally, totaling around 190 million women and girls, according to the World Health Organization.
Pearsanta’s Mitomic® Endometriosis Test (MET™) detects a specific deletion in mitochondrial DNA (mtDNA), which serves as a novel biomarker for endometriosis. Currently, there are no validated blood-based tests for this condition available in the U.S. or worldwide.
Under a new collaboration agreement, Evofem and Pearsanta will work together to create a comprehensive market strategy for the MET ahead of its planned U.S. launch in mid-2025. So far, over 300 cases of endometriosis have been evaluated using the MET, with plans to evaluate 600 more for clinical validation.
This partnership aligns with Evofem’s mission to enhance its portfolio of innovative women’s health products. The company currently markets a single-dose treatment for bacterial vaginosis and trichomoniasis, as well as a hormone-free contraceptive vaginal gel. Their long-term goal is to provide a full spectrum of healthcare solutions for women’s sexual and reproductive health.
Christopher Mitton, President of Pearsanta, stated, “Evofem’s expertise in women’s health makes them an ideal partner for the U.S. launch of our Mitomic Endometriosis Test. Their industry knowledge and relationships will be invaluable as we bring this innovative diagnostic to market.”
Endometriosis significantly impacts women’s health, with many experiencing chronic pelvic pain and infertility—two major consequences of the condition. Early diagnosis is crucial for effective intervention, yet no validated blood-based diagnostic tests currently exist. Pearsanta aims to fill this gap with its MET.
Aditxt Co-Founder and CEO Amro Albanna remarked, “This partnership highlights our commitment to transforming high-impact innovations into reality. By advancing Pearsanta toward the commercialization of the MET, we support Evofem in expanding its portfolio and diversifying revenue streams.”
Evofem CEO Saundra Pelletier added, “With Pearsanta’s Mitomic Endometriosis Test, physicians will be empowered to diagnose and improve the lives of women suffering from this debilitating disease. We look forward to leveraging our relationships with healthcare providers to ensure a successful U.S. launch.”
Beyond the MET, this collaboration could further expand Evofem’s women’s health initiatives with future tests, including the Mitomic Ovarian Test for early ovarian cancer detection.
About the Mitomic Technology Platform
Pearsanta’s proprietary Mitomic® Technology Platform uses the unique properties of mitochondrial DNA for disease detection through non-invasive blood-based liquid biopsies. This platform aims to identify specific mtDNA mutations indicative of various diseases, focusing on early cancer detection and conditions like endometriosis.
About Pearsanta, Inc.
Pearsanta is a leader in precision health, specializing in early cancer detection through advanced diagnostic technologies. Its Mitomic Technology Platform enables high-accuracy, non-invasive tests aimed at transforming early disease detection and improving patient outcomes.
Mitomic® is a registered trademark, and MET™ is a trademark of Pearsanta, Inc.
